IMIG 2018 – Grosso et al. poster
Let's collaborate Boehringer Ingelheim

IMIG 2018 – Grosso et al. poster

Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma: Phase II biomarker data from the LUME-Meso study

Grosso F, Nowak AK, Steele N, Novello S, Popat S, Greillier L, John T, Leighl NB, Reck M, Pavlakis N, Sørensen JB, Planchard D, Ceresoli GL, Hughes BGM, Mazières J, Socinski MA, Salnikov AV, Kitzing T, Braunger J, Pietzko K and Scagliotti G

This poster is presented for scientific education and its content may go beyond the scope of the current market authorization for nintedanib in Canada.

Related articles

Learn more about the science behind this presentation in the papers and other materials below

 

Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled LUME-Meso trial

Grosso F et al. JCO 2017; DOI: 10.1200/JCO.2017.72.9012

LUME-Meso: design and rationale of the Phase III part of a placebo-controlled study of nintedanib and pemetrexed/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma

Scagliotti G et al. WCLC 2017; DOI: 10.1016/j.cllc.2017.03.010

Downloads

pdf nowak_wclc_presentation.pdf

Novak A et al. WCLC 2017; DOI: 10. 1016/j.jtho.2017.09.636

Back to top

Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: May 2018